Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
WVU011625: The Role of Scheduled Intravenous Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. Many of these toxicities may be exacerbated by dehydration and are commonly managed with clinician-directed intravenous (IV) hydration. This study will evaluate whether scheduled IV hydration reduces the incidence and severity of treatment-related toxicities compared with clinician assessment-based hydration. Participants will be randomized 1:1 to scheduled IV hydration or clinician assessment-based IV hydration beginning in Week 3 of concurrent chemoradiotherapy and continuing through one week following completion of chemoradiotherapy.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Nina Moore
- 電話番号:304-293-2991
- メール:nina.moore@hsc.wvu.edu
研究連絡先のバックアップ
- 名前:Ella Betler
- 電話番号:304-293-4273
- メール:eibetler@hsc.wvu.edu
研究場所
-
-
West Virginia
-
Bridgeport、West Virginia、アメリカ、26330
- まだ募集していません
- WVU Medicine United Hospital Center
-
コンタクト:
- Sabrina Rexroad
- 電話番号:681-342-1000
- メール:sabrina.rexroad1@wvumedicine.org
-
Martinsburg、West Virginia、アメリカ、25401
- まだ募集していません
- WVU Medicine Berkeley Medical Center
-
コンタクト:
- Valli White
- 電話番号:304-264-1220
- メール:valli.white@wvumedicine.org
-
Morgantown、West Virginia、アメリカ、26506
- 募集
- West Virginia University Cancer Institute
-
コンタクト:
- Nina Moore
- 電話番号:304-293-2991
- メール:nina.moore@hsc.wvu.edu
-
主任研究者:
- David Clump, MD, PhD
-
主任研究者:
- Sidra Najeeb, MD
-
コンタクト:
- Ella Betler
- 電話番号:304-293-4273
- メール:eibetler@hsc.wvu.edu
-
Parkersburg、West Virginia、アメリカ、26101
- まだ募集していません
- WVU Medicine Camden Clark Medical Center
-
コンタクト:
- Layla Tannaoury
- 電話番号:304-424-2585
- メール:Layla.tannoury@wvumedicine.org,
-
Princeton、West Virginia、アメリカ、24740
- まだ募集していません
- WVU Medicine Princeton Community Hospital
-
コンタクト:
- Melissa Boggess
- 電話番号:304-487-7515
- メール:melissa.boggess1@wvumedicine.org
-
Wheeling、West Virginia、アメリカ、26003
- まだ募集していません
- WVU Medicine Wheeling Hospital
-
コンタクト:
- Maher Kali
- 電話番号:304-243-7045
- メール:maher.kali@wvumedicine.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- ECOG 0-2
- Non-nasopharyngeal squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx primary
- Planned for concurrent chemoradiotherapy (CCRT) with standard-of-care cisplatin-based regimen (IV cisplatin 100mg/m2 once every three weeks for up to three doses or IV cisplatin 40mg/m2 weekly) with concurrent radiotherapy (treatment duration approximately 6-7 weeks, per institutional standards).
- The use of immunotherapy in combination with CCRT is permitted and does not affect eligibility or group assignment.
Exclusion Criteria:
- Nasopharyngeal squamous cell carcinomas, nasal cavity and paranasal sinus squamous cell carcinomas.
- History of congestive heart failure.
- Dependency on enteral nutrition and hydration prior to enrollment.
- Use of diuretics that cannot be safely held during study treatment (participants who are able to temporarily discontinue diuretics during treatment are eligible).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Scheduled IV Hydration
Participants will receive scheduled IV hydration approximately twice per week throughout the treatment period. IV fluids will continue even if chemoradiotherapy infusion is held due to toxicities or cytopenias. |
Normal saline (0.9% sodium chloride) 1L of saline will be administered at each hydration visit. Participants will receive IV fluids on a planned schedule of twice a week, starting in Week 3 of chemoradiation treatment and continuing for one week after treatment is completed. |
|
他の:Clinician Assessment-Based IV Hydration
Participants will receive IV fluids (normal saline) only as clinically indicated and ordered by their treating clinician, per standard of care. IV fluids may continue if chemoradiotherapy infusion is held due to toxicities or cytopenias, at the discretion of the treating clinician. |
IV fluids (normal saline (0.9% sodium chloride)) only as clinically indicated and ordered by their treating clinician, per standard of care. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of at least one Grade ≥3 Treatment-Related Toxicities of Interest
時間枠:From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of participants experiencing at least one Grade ≥3 according to National Cancer Institute Common Terminology Criteria for Adverse Events v6.0 (NCI CTCAE) treatment-related toxicity of interest, including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, or trismus, during concurrent chemoradiotherapy. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidences of Individual Treatment-Related Toxicities of Interest
時間枠:From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of treatment-related mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus of any grade, as assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
|
Incidence of Enteric Tube Placement
時間枠:From initiation of treatment through 6 months after completion of chemoradiotherapy
|
Incidence of participants requiring enteric feeding tube placement during treatment and follow-up. |
From initiation of treatment through 6 months after completion of chemoradiotherapy
|
|
Incidence of Hematologic Toxicities
時間枠:Weeks 3-6 of concurrent chemoradiotherapy
|
Incidence of leukopenia, anemia, and thrombocytopenia assessed during weeks 3-6 of concurrent chemoradiotherapy treatment as assessed according to NCI CTCAE v6.0. |
Weeks 3-6 of concurrent chemoradiotherapy
|
|
Residual Grade of Toxicities of Interest at 3 Months
時間枠:3 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Residual grade of Toxicities of Interest at 6 Months
時間枠:6 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 3 Months
時間枠:3 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 6 Months
時間枠:6 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sidra Najeeb, MD、WVU Cancer Center
- スタディチェア:David Clump, MD, PhD、WVU Cancer Center
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY00000501
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data collected during the study, including demographic information, eligibility criteria, treatment/exposure data, outcome assessments, and relevant follow-up data, will be made available to qualified researchers. Data that could directly identify participants will not be shared.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。